Clinical Trials · NCT02557620
Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 113
- Start date
- Sep 2015
- Locations
- 1 site, Germany
- Primary endpoint
- Area under the semaglutide concentration-time curves